BLACK FRIDAY STARTS NOW! 30% Off Everything*! USE PROMO CODE: BLACK 

Recent Advances in Stroke Therapeutics

by Manzoor Ahmad Mir | 01 June 2014
Category: Medical Academic
Synopsis
Strokes are a leading cause of brain injury that strike approximately 800,000 people per year in the US alone, killing about 150,000 meaning one death in every four minutes. According to World Health Organization, 15 million people suffer strokes world-wide each year and out of these, 5 million die and another 5 million are permanently disabled. Despite advances in stroke research during last decade, current strokes remain a vexing public health problem. Even with the onset of the 21st century, there is still no effective therapy for strokes beyond a limited group of patients who are treated with thrombolytics, which have significant adverse effects. This situation prevails despite intense research efforts and numerous clinical trials that have attempted to develop drugs to reduce morbidity and mortality from strokes. So far, drug development efforts have targeted modulators of ion channels (Ca2+and Na+), scavengers of oxygen radicals, and antagonists of excitotoxic neurotransmitters (primarily glutamate and glycine receptors). Despite tremendous progress in understanding the pathophysiology of a stroke, translation of this knowledge into effective therapies has largely failed, with the exception of thrombolysis, which only benefits a small proportion of patients. Systemic and local immune responses have important roles in causing stroke and are implicated in the primary and secondary progression of ischaemic lesions, as well as in repair, recovery, and overall outcome after a stroke. However, potential therapeutic targets in the immune system and inflammatory responses have not been well characterised. The development of novel and effective therapeutic strategies for strokes will require further investigation of these pathways in terms of their temporal profile (before, during, and after stroke) and risk-to-benefit therapeutic ratio of modulating them.
€226.79
680 Reward Points
In stock online
Delivery in 5-7 Days
Eligible for free delivery

Any purchases for more than €10 are eligible for free delivery anywhere in the UK or Ireland!

Synopsis
Strokes are a leading cause of brain injury that strike approximately 800,000 people per year in the US alone, killing about 150,000 meaning one death in every four minutes. According to World Health Organization, 15 million people suffer strokes world-wide each year and out of these, 5 million die and another 5 million are permanently disabled. Despite advances in stroke research during last decade, current strokes remain a vexing public health problem. Even with the onset of the 21st century, there is still no effective therapy for strokes beyond a limited group of patients who are treated with thrombolytics, which have significant adverse effects. This situation prevails despite intense research efforts and numerous clinical trials that have attempted to develop drugs to reduce morbidity and mortality from strokes. So far, drug development efforts have targeted modulators of ion channels (Ca2+and Na+), scavengers of oxygen radicals, and antagonists of excitotoxic neurotransmitters (primarily glutamate and glycine receptors). Despite tremendous progress in understanding the pathophysiology of a stroke, translation of this knowledge into effective therapies has largely failed, with the exception of thrombolysis, which only benefits a small proportion of patients. Systemic and local immune responses have important roles in causing stroke and are implicated in the primary and secondary progression of ischaemic lesions, as well as in repair, recovery, and overall outcome after a stroke. However, potential therapeutic targets in the immune system and inflammatory responses have not been well characterised. The development of novel and effective therapeutic strategies for strokes will require further investigation of these pathways in terms of their temporal profile (before, during, and after stroke) and risk-to-benefit therapeutic ratio of modulating them.
Quantity
Quantity
€226.79
680 Reward Points
In stock online
Delivery in 5-7 Days
Eligible for free delivery

Any purchases for more than €10 are eligible for free delivery anywhere in the UK or Ireland!

Quantity
Quantity

Product Details

ISBN - 9781631177545
Format -
Publisher -
Published - 01/06/2014
Categories - All, Books, Education, Medical Academic
No. of Pages - 261
Weight - 588
Edition -
Series - - Not Available
Page Size - 26
Language - en-US
Readership Age - Not Available
Table of Contents - Not Available

Delivery And Returns

Please Note: Items in our extended range may take longer to deliver. Delivery in 5-7 Days

Place an order for over €10 to receive free delivery to anywhere in Ireland and the UK! See our Delivery Charges section below for a full breakdown of shipping costs for all destinations.

 

Delivery Charges

  Ireland & UK* Europe & USA Australia & Canada Rest of World
Under €10 €3.80 €10 €15 €25
Over €10
Free €10 €15 €25

*Free delivery on all orders over €10 - only applies to order total.

All orders will be delivered by An Post.